Ibrahim Turkoz
About
Ibrahim Turkoz is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology.
According to data from OpenAlex, Ibrahim Turkoz has authored 98 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Psychiatry and Mental health, 30 papers in Pharmacology and 21 papers in Clinical Psychology. Recurrent topics in Ibrahim Turkoz's work include Schizophrenia research and treatment (66 papers), Treatment of Major Depression (30 papers) and Bipolar Disorder and Treatment (26 papers). Ibrahim Turkoz is often cited by papers focused on Schizophrenia research and treatment (66 papers), Treatment of Major Depression (30 papers) and Bipolar Disorder and Treatment (26 papers). Ibrahim Turkoz collaborates with scholars based in United States, Belgium and China. Ibrahim Turkoz's co-authors include Cynthia A. Bossie, Ramy Mahmoud, Carla M. Canuso, Larry Alphs, Gahan Pandina, Georges M. Gharabawi, Dong‐Jing Fu, Mary J. Kujawa, Jean‐Pierre Lindenmayer and Nina R. Schooler and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and American Journal of Psychiatry.
In The Last Decade
Ibrahim Turkoz
92 papers receiving 1.7k citations
Peers
Ibrahim Turkoz
Mary Hobart United States
Georges M. Gharabawi United States
Philipp Rothe Germany
Pierre V. Trân United States
Spyridon Siafis Germany
Douglas L. Boggs United States
Caroline Corves Germany
Amir H Kalali United States
Jayendra K. Patel United States
Claudia Leucht Germany
Citations per year, relative to Ibrahim Turkoz Ibrahim Turkoz (= 1×)
peers
Mary Hobart
Countries citing papers authored by Ibrahim Turkoz
Since
Specialization
Citations
This map shows the geographic impact of Ibrahim Turkoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ibrahim Turkoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ibrahim Turkoz more than expected).
Fields of papers citing papers by Ibrahim Turkoz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ibrahim Turkoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ibrahim Turkoz. The network helps show where Ibrahim Turkoz may publish in the future.
Co-authorship network of co-authors of Ibrahim Turkoz
This figure shows the co-authorship network connecting the top 25 collaborators of Ibrahim Turkoz. A scholar is included among the top collaborators of Ibrahim Turkoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ibrahim Turkoz. Ibrahim Turkoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Turkoz, Ibrahim, et al.. (2024). Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. The International Journal of Neuropsychopharmacology. 27(2).
2.
Sliwa, Jennifer Kern, et al.. (2024). Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery–Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. CNS Spectrums. 29(3). 176–186.
3.
Correll, Christoph U., et al.. (2024). Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. CNS Spectrums. 29(6). 633–639.
4.
Alphs, Larry, Martha Sajatovic, Ibrahim Turkoz, et al.. (2023). Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia. The Journal of Clinical Psychiatry. 84(6).
5.
Wilkinson, Samuel T., et al.. (2023). Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs. 37(8). 715–723.
6.
Turkoz, Ibrahim, Mehmet Daskiran, H. Lynn Starr, et al.. (2022). Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment. Volume 18. 1927–1937.
7.
Williamson, David J., Keith H. Nuechterlein, Todd A. Tishler, et al.. (2022). Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective. Schizophrenia Research Cognition. 30. 100270–100270.
8.
Turkoz, Ibrahim, Ella Daly, Jaskaran Singh, et al.. (2021). Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response. The Journal of Clinical Psychiatry. 82(4).
9.
Canuso, Carla M., Dawn F. Ionescu, Xiang Li, et al.. (2021). Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. Journal of Clinical Psychopharmacology. 41(5). 516–524.
10.
Alphs, Larry, Dong‐Jing Fu, David J. Williamson, et al.. (2020). Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment. Psychiatry Research. 294. 113495–113495.
11.
Turkoz, Ibrahim, et al.. (2019). Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. SHILAP Revista de lepidopterología.
12.
Li, Huafang, et al.. (2018). Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study. Neuropsychiatric Disease and Treatment. Volume 14. 1107–1117.
13.
Turkoz, Ibrahim, Wing Chow, Larry Alphs, et al.. (2018). Interpretation of Change In Patient-Reported Outcomes in Treatment-Resistant Depression. Value in Health. 21. S187–S187.
14.
Fu, Dong‐Jing, Ibrahim Turkoz, David P. Walling, et al.. (2017). Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research. 192. 185–193.
15.
Pandina, Gahan, Ibrahim Turkoz, & Cynthia A. Bossie. (2013). Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder. Journal of Affective Disorders. 151(1). 384–391.
16.
Markowitz, Michael A., Dong‐Jing Fu, Bennett Levitan, et al.. (2013). Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry. 12(1). 22–22.
17.
Pandina, Gahan, Robert M. Bilder, Ibrahim Turkoz, & Larry Alphs. (2012). Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophrenia Research. 143(2-3). 312–318.
18.
Macfadden, Wayne, Larry Alphs, J. Thomas Haskins, et al.. (2009). A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders. 11(8). 827–839.
19.
Rapaport, Mark Hyman, Georges M. Gharabawi, Carla M. Canuso, et al.. (2006). Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology. 31(11). 2505–2513.
20.
Simpson, George M., Ramy Mahmoud, Robert Lasser, et al.. (2006). A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder. The Journal of Clinical Psychiatry. 67(8). 1194–1203.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mary Hobart Breakdown of academic impact, for papers by Georges M. Gharabawi Breakdown of academic impact, for papers by Philipp Rothe Breakdown of academic impact, for papers by Pierre V. Trân Breakdown of academic impact, for papers by Spyridon Siafis Breakdown of academic impact, for papers by Douglas L. Boggs Breakdown of academic impact, for papers by Caroline Corves Breakdown of academic impact, for papers by Amir H Kalali Breakdown of academic impact, for papers by Jayendra K. Patel Breakdown of academic impact, for papers by Claudia Leucht